Protenus Granted Sixth Patent for Drug Diversion Surveillance Technology

Protenus, Inc., a leading healthcare compliance analytics platform, has been granted a new U.S. patent, marking a significant advancement in its drug diversion surveillance technology. Announced on March 26, 2024, the Baltimore-based company's latest patent, U.S. Patent No. 11,923,062, is titled "Methods and Systems for Analyzing Accessing of Drug Dispensing Systems." This achievement underlines Protenus's efforts in enhancing hospital and health system efficiencies and proactively mitigating risks.

The newly issued patent encompasses a range of techniques, including pattern-based algorithms within an AI-driven approach, to detect anomalous drug dispensing events. Nick Culbertson, CEO and co-founder of Protenus, highlighted the company’s capability in identifying drug diversion early, aiming to address the concerning statistic that one in every 100 healthcare employees may be diverting narcotics away from patient care. Culbertson emphasized the importance of supporting customers’ diversion monitoring strategies without burdensome manual processes.

With this recent patent, Protenus holds over a dozen U.S. patents relating to patient privacy monitoring and drug diversion surveillance. The company’s innovative and award-winning solutions affirm its dedication to leveraging AI for scalable risk-reduction in healthcare, ensuring safety and protecting organizational reputations. Protenus also mentioned its recognition for excellence, including consecutive Best in KLAS awards and being named among America's Best Startup Employers by Forbes.